Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Single-center, Randomized, Open-label, Parallel Design Clinical Trial to Compare the 14-day Bismuth Quadruple Therapy and 7-day Culture Based Tailored Therapy for the Eradication of Helicobacter as a Rescue 2nd Therapy.

NCT02359331 is registered in ClinicalTrials.gov with Seoul National University Bundang Hospital as lead sponsor.

NCT NCT02359331
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02359331 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Single-center, Randomized, Open-label, Parallel Design Clinical Trial to Compare the 14-day Bismuth Quadruple Therapy and 7-day Culture Based Tailored Therapy for the Eradication of Helicobacter as a Rescue 2nd Therapy.
Lead sponsor
Seoul National University Bundang Hospital
Phase
Not applicable
Overall status
Terminated
Start date
August 31, 2014
Completion date
December 1, 2022
Enrollment
370 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

helicobacter infection